CD19 and lymphoma: Gauthier and collaborators (158) from the Seattle group re-infused their own CAR-T product (see section Other Anti-CD19 CAR-T Products with a 4-1BB Costimulatory Domain) in patients with R/R leukaemia and lymphoma.